Similar articles

• Leflunomide treatment of Crohn's disease patients intolerant to standard immunomodulator therapy.

  Prajapati DN, Knox JF, Emmons J, Saeian K, Csuka ME, Binion DG. Prajapati DN, et al. J Clin Gastroenterol. 2003 Aug;37(2):125-8. doi: 10.1097/00004836-200308000-00006. J Clin Gastroenterol. 2003. PMID: 12869881
• Treatment of Crohn's disease with leflunomide as second-line immunosuppression : a phase 1 open-label trial on efficacy, tolerability and safety.

  Holtmann MH, Gerts AL, Weinman A, Galle PR, Neurath MF. Holtmann MH, et al. Dig Dis Sci. 2008 Apr;53(4):1025-32. doi: 10.1007/s10620-007-9953-7. Epub 2007 Oct 13. Dig Dis Sci. 2008. PMID: 17934840 Clinical Trial.
• Safety and efficacy of leflunomide in the treatment of lupus nephritis refractory or intolerant to traditional immunosuppressive therapy: an open label trial.

  Tam LS, Li EK, Wong CK, Lam CW, Li WC, Szeto CC. Tam LS, et al. Ann Rheum Dis. 2006 Mar;65(3):417-8. doi: 10.1136/ard.2005.044248. Ann Rheum Dis. 2006. PMID: 16474039 Free PMC article. Clinical Trial. No abstract available.
• Tolerance or accommodation: the lesson from leflunomide.

  Sebille F, Dorling A. Sebille F, et al. Transplantation. 2005 Jan 27;79(2):133-4. doi: 10.1097/01.tp.0000147463.92625.14. Transplantation. 2005. PMID: 15665759 Review. No abstract available.
• Leflunomide use in renal transplantation.

  Leca N. Leca N. Curr Opin Organ Transplant. 2009 Aug;14(4):370-4. doi: 10.1097/MOT.0b013e32832dbc48. Curr Opin Organ Transplant. 2009. PMID: 19512928 Review.